Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
US FDA sees role for postmarketing data to help address residual uncertainties and determine additional data needs, but not as basis for securing an interchangeability designation absent a clinical, multi-switching study, draft guidance states.